Senolytic UBX0101 — Targeted p53/MDM2 Inhibition

UBX0101 functions as a targeted inhibitor of the interaction between the tumor suppressor protein p53 and its negative regulator MDM2. In senescent cells, p53 is often sequestered by MDM2, preventing apoptosis and allowing the cells to survive while secreting pro-inflammatory senescence-associated secretory phenotype (SASP) factors. By binding to MDM2, UBX0101 liberates p53, which then triggers apoptotic pathways specifically in these damaged cells. In preclinical models, this targeted senolysis reduced oxidative protein stress, attenuated SASP expression, and promoted the synthesis of cartilage-related extracellular matrix proteins in arthritic joints.

UBX0101 was evaluated in human clinical trials for moderate-to-severe painful knee osteoarthritis. While a Phase 1 trial demonstrated that single intra-articular injections were well-tolerated, a subsequent Phase 2 randomized, double-blind, placebo-controlled trial failed to meet its primary endpoint, showing no significant improvement in WOMAC pain scores at 12 weeks compared to placebo. Following these results in 2020, clinical development of UBX0101 for osteoarthritis was halted.

In clinical trials, UBX0101 was administered as a single intra-articular (IA) injection directly into the knee joint at doses up to 4.0 mg. It is an experimental compound whose clinical development was halted; dosing, frequency, and efficacy in humans remain unestablished.

Single intra-articular injections up to 4.0 mg were generally well-tolerated in short-term clinical trials, with no serious adverse events reported. As an experimental senolytic that modulates apoptotic pathways, potential long-term systemic effects, contraindications, and drug interactions are unknown. It is not approved or available for human use.

Key Papers